Noxopharm Limited (NOXOF)
USD 0.05
(-88.46%)
USD 0.05
(-88.46%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -3.57 Million AUD | 76.24% |
| 2023 | -15.05 Million AUD | 19.34% |
| 2022 | -18.66 Million AUD | -99.71% |
| 2021 | -9.34 Million AUD | -3335.13% |
| 2020 | -272.09 Thousand AUD | 97.58% |
| 2019 | -11.22 Million AUD | 38.62% |
| 2018 | -18.28 Million AUD | -500.27% |
| 2017 | -3.04 Million AUD | -332.21% |
| 2016 | -704.72 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -540.09 Thousand AUD | 78.38% |
| 2024 FY | -3.57 Million AUD | 76.24% |
| 2024 Q1 | -1.24 Million AUD | 87.03% |
| 2024 Q2 | -2.49 Million AUD | -100.0% |
| 2024 Q4 | -540.09 Thousand AUD | 0.0% |
| 2023 FY | -15.05 Million AUD | 19.34% |
| 2023 Q3 | -4.81 Million AUD | 11.28% |
| 2023 Q4 | -9.62 Million AUD | -100.0% |
| 2023 Q2 | -5.42 Million AUD | -100.0% |
| 2023 Q1 | -2.71 Million AUD | 73.01% |
| 2022 Q2 | -8.61 Million AUD | -100.0% |
| 2022 Q4 | -10.05 Million AUD | -100.0% |
| 2022 FY | -18.66 Million AUD | -99.71% |
| 2022 Q1 | -4.3 Million AUD | -64.1% |
| 2022 Q3 | -5.02 Million AUD | 41.63% |
| 2021 Q2 | -6.72 Million AUD | -100.0% |
| 2021 FY | -9.34 Million AUD | -3335.13% |
| 2021 Q3 | -1.31 Million AUD | 80.48% |
| 2021 Q4 | -2.62 Million AUD | -100.0% |
| 2021 Q1 | -3.36 Million AUD | -150.33% |
| 2020 Q4 | 6.67 Million AUD | 100.0% |
| 2020 FY | -272.09 Thousand AUD | 97.58% |
| 2020 Q2 | -6.94 Million AUD | -100.0% |
| 2020 Q1 | -3.47 Million AUD | 48.66% |
| 2020 Q3 | 3.33 Million AUD | 148.04% |
| 2019 Q1 | -1.79 Million AUD | 42.85% |
| 2019 Q4 | -6.76 Million AUD | -77.51% |
| 2019 Q3 | -3.81 Million AUD | -112.05% |
| 2019 Q2 | -1.79 Million AUD | 0.0% |
| 2019 FY | -11.22 Million AUD | 38.62% |
| 2018 Q4 | -3.14 Million AUD | 0.0% |
| 2018 FY | -18.28 Million AUD | -500.27% |
| 2018 Q1 | -5.99 Million AUD | -528.82% |
| 2018 Q2 | -5.99 Million AUD | 0.0% |
| 2018 Q3 | -3.14 Million AUD | 47.52% |
| 2017 FY | -3.04 Million AUD | -332.21% |
| 2017 Q1 | -569.53 Thousand AUD | 5.48% |
| 2017 Q4 | -953.41 Thousand AUD | 0.0% |
| 2017 Q2 | -569.53 Thousand AUD | 0.0% |
| 2017 Q3 | -953.41 Thousand AUD | -67.4% |
| 2016 FY | -704.72 Thousand AUD | 0.0% |
| 2016 Q2 | -96.26 Thousand AUD | 0.0% |
| 2016 Q4 | -602.58 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Qrons Inc. | -789.34 Thousand USD | -353.301% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.494% |
| Nascent Biotech, Inc. | -2.08 Million USD | -71.392% |
| Adynxx, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 77.456% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 6.307% |
| BioStem Technologies, Inc. | -8.48 Million USD | 57.82% |
| CSL Limited | 2.64 Billion USD | 100.135% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 48.758% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 106.754% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.284% |
| Regen BioPharma, Inc. | 1.02 Million USD | 449.593% |
| Skye Bioscience, Inc. | -37.64 Million USD | 90.495% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -761.203% |
| Rebus Holdings, Inc. | -1.02 Million USD | -250.796% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -167.937% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -465.793% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.227% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 45.589% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1208.738% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.497% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -23.708% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -96.543% |
| Mesoblast Limited | -87.95 Million USD | 95.932% |
| Marizyme, Inc. | -65.34 Million USD | 94.524% |
| Genus plc | 7.9 Million USD | 145.293% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 67.148% |
| Pharming Group N.V. | -10.54 Million USD | 66.078% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -64.904% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 3.561% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 59.542% |
| ContraFect Corporation | -65.15 Million USD | 94.508% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 26.769% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -107.132% |
| IMV Inc. | -36.48 Million USD | 90.193% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 55.605% |
| MultiCell Technologies, Inc. | -380.07 USD | -941336.314% |
| ONE Bio Corp. | 8.67 Million USD | 141.239% |
| Accustem Sciences Inc. | -3.74 Million USD | 4.492% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.078% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -182.379% |
| Q BioMed Inc. | -2.05 Million USD | -74.364% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 4.149% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -50.286% |
| Biomind Labs Inc. | -1.21 Million USD | -194.66% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.009% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -15.357% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 54.725% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -83.564% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -23792.341% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 38.491% |
| GB Sciences, Inc. | -1.36 Million USD | -162.773% |
| Alpha Cognition Inc. | -13.77 Million USD | 74.02% |
| HST Global, Inc. | -146.21 Thousand USD | -2347.245% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -103.908% |
| Halberd Corporation | -79.67 Thousand USD | -4390.834% |
| Enzolytics Inc. | -2.17 Million USD | -64.373% |
| Agentix Corp. | -1.37 Million USD | -160.376% |
| Resverlogix Corp. | -3.61 Million USD | 0.883% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -12.823% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.787% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3751.14% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 151.673% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 9.939% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -18.24% |
| AVAX Technologies, Inc. | -6.41 Million USD | 44.211% |
| Zenith Capital Corp. | -10.59 Million USD | 66.231% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.252% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -15295.048% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 13.696% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5820.054% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -78.449% |
| Kadimastem Ltd | -3.3 Million USD | -8.185% |
| Helix BioMedix, Inc. | -1.05 Million USD | -238.819% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -710.686% |
| LadRx Corporation | 400.44 Thousand USD | 993.54% |
| Cell Source, Inc. | -5.32 Million USD | 32.757% |
| Regen BioPharma, Inc. | 1.02 Million USD | 449.593% |
| NovAccess Global Inc. | -4.76 Million USD | 24.974% |
| Affymax, Inc. | -14.42 Million USD | 75.193% |
| Itoco Inc. | -1.86 Million USD | -91.446% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 19.458% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -114.387% |
| Mobile Lads Corp. | -2.26 Million USD | -58.093% |
| CytoDyn Inc. | -49.84 Million USD | 92.821% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4427.371% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1468.476% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -280.033% |
| SYBLEU INC | -180.3 Thousand USD | -1884.491% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -121.866% |
| International Stem Cell Corporation | -131 Thousand USD | -2631.387% |
| Bioxytran, Inc. | -4.28 Million USD | 16.399% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6492.934% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -41.414% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 92.557% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -69.258% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -358.212% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -12.946% |
| Neutra Corp. | -233.46 Thousand USD | -1432.614% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 82.366% |
| PureTech Health plc | -65.69 Million USD | 94.554% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 83.175% |
| IXICO plc | -1.17 Million USD | -203.745% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 63.956% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 93.737% |
| CSL Limited | 2.64 Billion USD | 100.135% |
| Cellectis S.A. | -103.17 Million USD | 96.532% |